LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40885527无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40885529无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40885530无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study.Clin Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40887341无 PMCID | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.UrologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40902908无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial.StrokePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40927857无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial.J Dermatolog TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40931395无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.Ann Oncol | PMID 40947016PMC12721713 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。 | PMID 40954943PMC12587258 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study.Ann Rheum DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40962616无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial.Allergy已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:森林图/亚组分析图;FIGURE 3:AI 判定为 other。 | PMID 40965045PMC12666762 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40967930无 PMCID | 2025-Dec | 0.95 | This is a randomized, phase 3 oncology trial with time-to-event efficacy endpoints (RFS, OS, CSS) and Kaplan-Meier/HR results. However, it compares two surgical techniques (lymph node dissection extent) and does not contain a drug-containing intervention as required. | 无 KM 图 |
| Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40972947无 PMCID | 2025-Dec | 0.95 | The record describes a Phase III randomized trial in human oncology with primary OS and secondary RFS endpoints, but it evaluates surveillance strategies (CT-scan, CEA testing) and not a drug intervention. The intervention is non-drug-only monitoring, which is excluded. | 无 KM 图 |
| Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial.J AutoimmunPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40974866无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.Diabetes Obes Metab入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40977363无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).J Gastroenterol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40982097PMC12630152 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.Lancet Respir Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40983066无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Model-Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation.CPT Pharmacometrics Syst Pharmacol已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。 | PMID 40990036PMC12706396 | 2025-Dec | 0.80 | The record describes a Phase III randomized controlled trial in oncology (CheckMate 67T) but focuses solely on pharmacokinetic analysis and model-informed drug development, not on reporting survival, progression, recurrence, death, or related efficacy outcomes for KM digitization. | 无 KM 图 |
| Early response to vunakizumab and its baseline predictors in patients with moderate-to-severe plaque psoriasis: a post hoc analysis of a phase-III trial.J Dermatolog TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40995857无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies.Adv Ther已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。 | PMID 41014486PMC12680862 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41015742无 PMCID | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China: a post-hoc exploratory analysis of a phase III, randomized controlled trial.J Dermatolog TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41020409无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.Nat Med已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 flow diagram;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:AI 判定为 other。 | PMID 41023483PMC12705446 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Beyond the first cut: Impact of repeat surgery versus boost on breast induration-A post hoc analysis from the DBCG HYPO & PBI trials.Breast | PMID 41043314PMC12516053 | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet Gastroenterol HepatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41043449无 PMCID | 2025-Dec | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation.Clin Genitourin Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41046201无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial.Clin TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41047325无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41057084无 PMCID | 2025-Dec | 0.45 | The record is a secondary analysis of a Phase III randomized trial in head and neck cancer, but it reports only acute toxicity endpoints (dysphagia, mucositis), not the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. Therefore, eligibility cannot be established. | 无 KM 图 |
| Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.Nat Med | PMID 41057655PMC12705445 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.Nat Med | PMID 41062831PMC12705423 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial.Allergy已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 forest plot;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:森林图/亚组分析图。 | PMID 41064908PMC12666737 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis.Osteoporos Int已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 multi panel km;Fig. 2:AI 判定为 other。 | PMID 41085683PMC12672812 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.J Clin Oncol | PMID 41092247PMC12634147 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial.Lancet Gastroenterol Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41101325无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Impact of comprehensive lifestyle interventions on plasma branched-chain amino acid concentrations: a randomized trial.Am J Clin NutrPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41106729PMC12799384 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus.Clin Pharmacokinet入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41107649无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.Nat Med | PMID 41109920PMC12705465 | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study.J Infect ChemotherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41110828无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| 177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41111031无 PMCID | 2025-Dec | 0.95 | The record describes an eligible Phase III randomized trial with a drug intervention and a primary time-to-event endpoint (PFS). However, the inclusion criteria require the endpoint to be for efficacy and the report to be a primary result report. The abstract presents primary PFS results with HR, which is a time-to-event endpoint. The report includes QoL and safety data, but these are secondary. The deterministic review flagged drug intervention as unclear, but the abstract clearly describes XTR008 (177Lu-Dotatate) as a drug intervention vs. octreotide (a drug). Therefore, all criteria are met for eligibility, but the deterministic review's initial assessment was incorrect. The record is eligible as a primary result report. | 无 KM 图 |
| Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIG 1.:AI 判定为 flow diagram;FIG 2.:AI 判定为 other;FIG 3.:非 KM 图。 | PMID 41115259PMC12634144 | 2025-Dec | 0.95 | Meets all criteria: Phase III randomized drug trial in human oncology (desmoid tumors) with a primary time-to-event (PFS) endpoint and original result reporting. | 无 KM 图 |
| Microbiome and metabolome changes after fecal microbiota, live-jslm, administration are associated with health-related quality of life improvements.AnaerobePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41115624无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.Nat MedAI 判定该论文不进入自动 KM 提取:This is a phase 2/3 trial, not exclusively Phase III. The publication types list both 'Clinical Trial, Phase III' and 'Clinical Trial, Phase II', indicating a combined phase design. | PMID 41115959无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial.Aliment Pharmacol Ther已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:森林图/亚组分析图;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。 | PMID 41127972PMC12646629 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.Sleep Med已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:AI 判定为 other;Fig. 2.:AI 判定为 multi panel km;Fig. 3.:AI 判定为 other;Fig. 4.:AI 判定为 other。 | PMID 41135142PMC12723708 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41137844无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Variable Selection via Fused Sparse-Group Lasso Penalized Multi-state Models Incorporating Molecular Data.Biom J已检查 14 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other;另有 9 张未列出。 | PMID 41146443PMC12559784 | 2025-Dec | 0.45 | While the trial registration and publication metadata suggest an oncology Phase III randomized trial, the abstract describes a methodological/statistical analysis (proposing a variable selection algorithm) applied to trial data, not a formal report of the trial's efficacy results. The presence of a drug intervention is not established in the abstract, and no primary time-to-event endpoint is reported. | 无 KM 图 |
| Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41166665无 PMCID | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41167231无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma.Clin TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41168047无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| High Loss of Adipose Tissue During Neoadjuvant Chemotherapy Predicts Poor Prognosis in Patients With Gastric Cancer.J Cachexia Sarcopenia Muscle | PMID 41168973PMC12575444 | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |